Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Arcutis Biotherapeutics I...

    NASDAQ: ARQT · Real-Time Price · USD
    13.45
    -0.05 (-0.37%)
    At close: Jun 13, 2025, 3:59 PM
    13.47
    0.19%
    After-hours: Jun 13, 2025, 07:51 PM EDT

    Arcutis Biotherapeutics Statistics

    Share Statistics

    Arcutis Biotherapeutics has 119.2M shares outstanding. The number of shares has increased by 2.48% in one year.

    Shares Outstanding

    n/a
    		 119.2M

    Shares Change (YoY)

    n/a
    		 2.48%

    Shares Change (QoQ)

    n/a
    		 1.36%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 104.81M

    Failed to Deliver (FTD) Shares

    n/a
    		 589

    FTD / Avg. Volume

    n/a
    		 0.03%

    Short Selling Information

    The latest short interest is 16.78M, so 14.07% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 16.78M

    Short % of Shares Out

    n/a
    		 14.07%

    Short % of Float

    n/a
    		 17.41%

    Short Ratio (days to cover)

    n/a
    		 8.45

    Valuation Ratios

    The PE ratio is -12.03 and the forward PE ratio is 67.47. Arcutis Biotherapeutics's PEG ratio is 0.17.

    PE Ratio

    n/a
    		 -12.03

    Forward PE

    n/a
    		 67.47

    PS Ratio

    n/a
    		 8.57

    Forward PS

    n/a
    		 2

    PB Ratio

    n/a
    		 10.7

    P/FCF Ratio

    n/a
    		 -15

    PEG Ratio

    n/a
    		 0.17
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Arcutis Biotherapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.7.

    Current Ratio

    n/a
    		 4.15

    Quick Ratio

    n/a
    		 3.97

    Debt / Equity

    n/a
    		 0.7

    Debt / EBITDA

    n/a
    		 -1.01

    Debt / FCF

    n/a
    		 -0.98

    Interest Coverage

    n/a
    		 -4.73

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $574,684.21

    Profits Per Employee

    n/a
    		 $-409,470.76

    Employee Count

    n/a
    		 342

    Asset Turnover

    n/a
    		 0.56

    Inventory Turnover

    n/a
    		 1.32

    Taxes

    Income Tax

    n/a
    		 647K

    Effective Tax Rate

    n/a
    		 -0.46%

    Stock Price Statistics

    The stock price has increased by 55.85% in the last 52 weeks. The beta is 1.78, so Arcutis Biotherapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.78

    52-Week Price Change

    n/a
    		 55.85%

    50-Day Moving Average

    n/a
    		 13.96

    200-Day Moving Average

    n/a
    		 12.61

    Relative Strength Index (RSI)

    n/a
    		 45.14

    Average Volume (20 Days)

    n/a
    		 2,323,506

    Income Statement

    In the last 12 months, Arcutis Biotherapeutics had revenue of 196.54M and earned -140.04M in profits. Earnings per share was -1.16.

    Revenue

    n/a
    		 196.54M

    Gross Profit

    n/a
    		 177.41M

    Operating Income

    n/a
    		 -128.4M

    Net Income

    n/a
    		 -140.04M

    EBITDA

    n/a
    		 -109.63M

    EBIT

    n/a
    		 -112.22M

    Earnings Per Share (EPS)

    n/a
    		 -1.16
    Full Income Statement

    Balance Sheet

    The company has 71.33M in cash and 110.58M in debt, giving a net cash position of -39.25M.

    Cash & Cash Equivalents

    n/a
    		 71.33M

    Total Debt

    n/a
    		 110.58M

    Net Cash

    n/a
    		 -39.25M

    Retained Earnings

    n/a
    		 -1.12B

    Total Assets

    n/a
    		 344.11M

    Working Capital

    n/a
    		 232.54M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -112.16M and capital expenditures -143K, giving a free cash flow of -112.3M.

    Operating Cash Flow

    n/a
    		 -112.16M

    Capital Expenditures

    n/a
    		 -143K

    Free Cash Flow

    n/a
    		 -112.3M

    FCF Per Share

    n/a
    		 -0.93
    Full Cash Flow Statement

    Margins

    Gross margin is 90.27%, with operating and profit margins of -65.33% and -71.25%.

    Gross Margin

    n/a
    		 90.27%

    Operating Margin

    n/a
    		 -65.33%

    Pretax Margin

    n/a
    		 -70.92%

    Profit Margin

    n/a
    		 -71.25%

    EBITDA Margin

    n/a
    		 -55.78%

    EBIT Margin

    n/a
    		 -65.33%

    FCF Margin

    n/a
    		 -57.14%

    Dividends & Yields

    ARQT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ARQT is $19.5, which is 45% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $19.5

    Price Target Difference

    n/a
    		 45%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 0.54

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist